Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Ophthalmology

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Acular (ketorolac tromethamine ophthalmic solution) 0.5%

Company: Allergan
Approval Status: Approved November 1997
Treatment Area: post-surgical inflammation following cataract extraction

General Information

Acular has now been approved by the FDA for post-surgical inflammation following cataract extraction. Acular is administered between one and four times daily starting 24 hours after surgery for two weeks. It can be used with antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. For itch, Acular is administered between one and four times daily as needed.

Side Effects

Adverse events include transient stinging and burning upon application.

Mechanism of Action

Acular (ketorolac tromethamine ophthalmic solution 0.5%) works by inhibiting prostaglandins in the aqueous humor. Allergan began marketing Acular in 1992 to treat seasonal conjunctival allergies, although the drug did find off-label uses for cystoid macular edemas and post-surgical inflammation.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.